Supplements

Solriamfetol improves objective wakefulness and reduces subjective sleepiness in Chinese OSA patients with EDS across all disease severity levels.

In a post hoc analysis of a 12-week RCT, solriamfetol (up to 150 mg/day) significantly prolonged MWT sleep latency vs placebo in all AHI subgroups: AHI<5 (LS mean difference 12.13 min, p<0.0001), 5≤AHI<30 (12.68 min, p<0.0001), and AHI≥30 (10.94 min, p=0.0001). ESS scores significantly improved in the two milder subgroups but not in the severe OSA subgroup (p=0.2497).

Last updated: Jul 15, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score48/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Post Hoc Analysis of Solriamfetol Efficacy in Obstructive Sleep Apnea Patients with Excessive Daytime Sleepiness Stratified by Disease Severity.

observational

Su C, Shen J, Guo K, Wang J, Wang Z, Gao S, Wang Q, Han F, Zhang W, Ye H, Li X, Zhang R, Chen R · Advances in therapy (2026)

Participants: N/A
Duration: 12 weeks
Intervention: Solriamfetol dose titrated up to 150 mg/day for 12 weeks
Outcome: Change from baseline in MWT mean sleep latency (min) and ESS score at week 12
Effect Size: MWT: LS mean difference vs placebo 12.13 to 12.68 min (AHI<5 and 5≤AHI<30); ESS: LS mean difference vs placebo -2.0 to -2.1 points (significant in milder subgroups only)
Population: Chinese OSA patients with excessive daytime sleepiness, stratified by baseline AHI (<5, 5 to <30, ≥30)

Result:

PubMed: 42423948DOI: 10.1007/s12325-026-03690-5

Mechanism Graph

Solriamfetol inhibits dopamine and norepinephrine reuptake
↓
Increased synaptic dopamine and norepinephrine levels
↓
Enhanced arousal and wake-promoting signaling in the brain
↓
Result: Improved objective wakefulness and reduced subjective sleepiness

Limitations

  • ⚠Post hoc subgroup analysis, not pre-specified as primary endpoint
  • ⚠ESS improvement not statistically significant in the severe OSA (AHI≥30) subgroup
  • ⚠Single Chinese population limits generalizability to other ethnic groups

Frequently Asked Questions

What is solriamfetol?▼

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with obstructive sleep apnea.

Did solriamfetol work equally well in all OSA severity groups?▼

Objective wakefulness (MWT) improved significantly in all AHI subgroups, but subjective sleepiness (ESS) only improved significantly in milder OSA (AHI<30) and not in severe OSA (AHI≥30).

What were the common side effects?▼

The most common adverse events (>10% incidence) included upper respiratory tract infection, hyperuricemia, dizziness, and hypertension.

How long was the treatment period?▼

The study lasted 12 weeks with dose titration up to 150 mg/day.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Su C, Shen J, Guo K, Wang J, Wang Z, Gao S, Wang Q, Han F, Zhang W, Ye H, Li X, Zhang R, Chen R. "Post Hoc Analysis of Solriamfetol Efficacy in Obstructive Sleep Apnea Patients with Excessive Daytime Sleepiness Stratified by Disease Severity.." Advances in therapy, 2026. PMID: 42423948 DOI: 10.1007/s12325-026-03690-5
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.